TLR9 Immunotherapy for Peritoneal Carcinomatosis

The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are: • To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal injection(s) of ACM-CpG for inoperable peritoneal metastases or malignant ascites? Researchers will assign treatment levels using escalating doses of ACM-CpG Therapy. Participants will: * Will receive at least one dose of ACM-CpG therapy on Day 1 of a 28-day treatment cycle. * May receive up to 2 add

Trial Details

NCT ID
NCT07658196
Phase
PHASE1
Sponsor
Brown University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • ACM-CpG
Locations (sample)
  • Providence, Rhode Island, United States|41.82399,-71.41283

Key Eligibility Criteria

  • Patients eligible for inclusion in this study must meet all of the following criteria:
  • Male or female patients age ≥ 18 years of age at the time of informed consent
  • Must be able to provide written informed consent, stating an understanding of the procedures and investigational nature of the study treatment, and…
  • Must have documented CRC or appendiceal adenocarcinoma peritoneal carcinomatosis or malignant ascites. Primary tumor may be intact and limited live…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →